Alpha cyclotron production studies of the alpha emitter 211At/211gPo for high-let metabolic radiotherapy

S. Morzenti, M. L. Bonardi, F. Groppi, C. Zona, L. Canella, E. Menapace, Z. B. Alfassi, K. Abbas, U. Holzwarth

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

1 Scopus citations

Abstract

A series of high specific activity accelerator-produced radionuclides in no-carrier-added (NCA) form, for uses in metabolic radiotherapy and for PET, has been investigated and produced at JRC-Ispra Cyclotron Laboratory. In this study we present, in particular, the NCA 211At/211gPo (LET = 130 eV.nm-1, t1/2= 7.214 h), produced by 209Bi(α,2n) reaction, with internal spike of gamma emitter 210At (e.g. negligible amount of 210Po as radiotoxic long-lived impurity), for high-LET targeted radiotherapy and immunoradiotherapy. A selective radiochemical separation, based on liquid/liquid extraction, of At radionuclides from Bi target and Po impurities has been developed. High resolution gamma, X and alpha spectrometric techniques have been adopted for quality controls of different radiochemical fractions.

Original languageEnglish
Title of host publicationAstroparticle, Particle and Space Physics, Detectors and Medical Physics Applications - Proceedings of the 9th Conference
Pages742-746
Number of pages5
StatePublished - 1 Dec 2006
EventInternational Conference on Advanced Technology and Particle Physics, ICATPP 2005 - Como, Italy
Duration: 17 Oct 200521 Oct 2005

Publication series

NameAstroparticle, Particle and Space Physics, Detectors and Medical Physics Applications - Proceedings of the 9th Conference

Conference

ConferenceInternational Conference on Advanced Technology and Particle Physics, ICATPP 2005
Country/TerritoryItaly
CityComo
Period17/10/0521/10/05

ASJC Scopus subject areas

  • Astronomy and Astrophysics
  • Nuclear and High Energy Physics

Fingerprint

Dive into the research topics of 'Alpha cyclotron production studies of the alpha emitter 211At/211gPo for high-let metabolic radiotherapy'. Together they form a unique fingerprint.

Cite this